Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alissa R Segal

Showing results (1-10 of 27) with videos related to

Pageof 3
Sort By:
Journal of Diabetes Science and Technology|November 12, 2014
Are you ready for more insulin concentrations?Alissa R Segal, Nuha El Sayed
Current Diabetes Reports|April 10, 2012
Treatment of type 2 diabetes in the elderlyMedha N Munshi, Megumi Maguchi, Alissa R Segal
Current Diabetes Reports|January 28, 2014
Diabetes in long-term care facilitiesAaditya Singhal, Alissa R Segal, Medha N Munshi
Endocrinology and Metabolism Clinics of North America|November 9, 2016
Insulin: Making Sense of Current OptionsAlissa R Segal, Tejaswi Vootla, Richard S Beaser
Journal of the American Geriatrics Society|February 3, 2017
Metformin-SGLT2, Dehydration, and Acidosis PotentialJohn A D'Elia, Alissa R Segal, Larry A Weinrauch
Pediatrics|October 3, 2007
Cutaneous reactions to drugs in childrenAlissa R Segal, Kevin M Doherty, John Leggott, et al.
Endocrinology, Diabetes & Metabolism|April 23, 2020
Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapyGregory P Westcott, Alissa R Segal, Joanna Mitri, et al.
American Journal of Lifestyle Medicine|January 24, 2025
Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes StudySultan Alolayan, Tewodros Eguale, Alissa R Segal, et al.
International Journal of Nephrology and Renovascular Disease|July 4, 2017
Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusionsJohn A D'Elia, Alissa R Segal, George P Bayliss, et al.
Diabetes, Obesity & Metabolism|August 14, 2024
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never wasBrian E Rittenhouse, Sultan Alolayan, Tewodros Eguale, et al.
Pageof 3

Showing results (1-10 of 27) with videos related to

Sort By:
Pageof 3
Journal of Diabetes Science and Technology|November 12, 2014
Are you ready for more insulin concentrations?Alissa R Segal, Nuha El Sayed
Current Diabetes Reports|April 10, 2012
Treatment of type 2 diabetes in the elderlyMedha N Munshi, Megumi Maguchi, Alissa R Segal
Current Diabetes Reports|January 28, 2014
Diabetes in long-term care facilitiesAaditya Singhal, Alissa R Segal, Medha N Munshi
Endocrinology and Metabolism Clinics of North America|November 9, 2016
Insulin: Making Sense of Current OptionsAlissa R Segal, Tejaswi Vootla, Richard S Beaser
Journal of the American Geriatrics Society|February 3, 2017
Metformin-SGLT2, Dehydration, and Acidosis PotentialJohn A D'Elia, Alissa R Segal, Larry A Weinrauch
Pediatrics|October 3, 2007
Cutaneous reactions to drugs in childrenAlissa R Segal, Kevin M Doherty, John Leggott, et al.
Endocrinology, Diabetes & Metabolism|April 23, 2020
Prolonged glucosuria and relapse of diabetic ketoacidosis related to SGLT2-inhibitor therapyGregory P Westcott, Alissa R Segal, Joanna Mitri, et al.
American Journal of Lifestyle Medicine|January 24, 2025
Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes StudySultan Alolayan, Tewodros Eguale, Alissa R Segal, et al.
International Journal of Nephrology and Renovascular Disease|July 4, 2017
Sodium-glucose cotransporter-2 inhibition and acidosis in patients with type 2 diabetes: a review of US FDA data and possible conclusionsJohn A D'Elia, Alissa R Segal, George P Bayliss, et al.
Diabetes, Obesity & Metabolism|August 14, 2024
Metformin in the Diabetes Prevention Program 3-year trial: The cost-effectiveness that never wasBrian E Rittenhouse, Sultan Alolayan, Tewodros Eguale, et al.
Pageof 3